Literature DB >> 20632026

The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment.

S Galluzzi1, C Geroldi, R Ghidoni, B Paghera, G Amicucci, M Bonetti, O Zanetti, M Cotelli, M Gennarelli, G B Frisoni.   

Abstract

To test the validity of the new diagnostic criteria for Alzheimer's disease (AD) in a naturalistic series of patients with mild cognitive impairment (MCI). Ninety consecutive MCI patients were enrolled in a longitudinal study on the natural history of cognitive impairment. Medial temporal (MT) atrophy on MRI was defined as hippocampal volume below the fifth percentile of the distribution in healthy elders, abnormal CSF was based on Sjogren's cutoffs for Abeta42 and tau, and temporoparietal hypometabolism on 18F-FDG PET based on Herholz's t sum score. Patients were followed clinically to detect conversion to AD (MCI-AD), non-AD dementia (MCI-nAD), or no conversion (MCI-NC). The 24 MCI-AD and 15 MCI-nAD patients had sociodemographic, clinical, and neuropsychological baseline features similar to the 51 MCI-NC patients. All MCI patients with MT atrophy converted to AD, as did all those with abnormal CSF, but only 48 and 35% of those without MT atrophy or abnormal CSF converted (p on logrank test = 0.0007 and 0.001). Prediction of AD conversion was enhanced when positivity to either MT atrophy or abnormal CSF was considered, with only 15% of those MCI patients negative on both converting to AD (p < 0.0005). Markers were not predictive of non-AD dementia conversion. The accuracy of either MT atrophy or abnormal CSF in discriminating MCI-AD from MCI-NC was good (AUC 0.82, 95% CI 0.70-0.95). MT atrophy and abnormal CSF are the single most robust predictors of conversion to AD in MCI patients, and their combination enhances prediction. AD markers are not predictive of conversion to non-AD dementia.

Entities:  

Mesh:

Year:  2010        PMID: 20632026     DOI: 10.1007/s00415-010-5650-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.

Authors:  N A Verwey; W M van der Flier; K Blennow; C Clark; S Sokolow; P P De Deyn; D Galasko; H Hampel; T Hartmann; E Kapaki; L Lannfelt; P D Mehta; L Parnetti; A Petzold; T Pirttila; L Saleh; A Skinningsrud; J C V Swieten; M M Verbeek; J Wiltfang; S Younkin; P Scheltens; M A Blankenstein
Journal:  Ann Clin Biochem       Date:  2009-04-02       Impact factor: 2.057

Review 3.  Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies.

Authors:  Michael D Devous
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-25       Impact factor: 9.236

4.  Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Authors:  D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

5.  The topography of grey matter involvement in early and late onset Alzheimer's disease.

Authors:  Giovanni B Frisoni; Michela Pievani; Cristina Testa; Francesca Sabattoli; Lorena Bresciani; Matteo Bonetti; Alberto Beltramello; Kiralee M Hayashi; Arthur W Toga; Paul M Thompson
Journal:  Brain       Date:  2007-02-09       Impact factor: 13.501

6.  Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.

Authors:  Sid Gilman; Robert A Koeppe; Roderick Little; Hyonggin An; Larry Junck; Bruno Giordani; Carol Persad; Mary Heumann; Kris Wernette
Journal:  Exp Neurol       Date:  2005-02       Impact factor: 5.330

7.  Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Authors:  Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

Review 8.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

Review 9.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

View more
  15 in total

Review 1.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Translation of imaging biomarkers from clinical research to healthcare.

Authors:  Ingo Kilimann; Jochen René Thyrian; Wolfgang Hoffmann; Stefan J Teipel
Journal:  Z Gerontol Geriatr       Date:  2017-04-12       Impact factor: 1.281

Review 3.  ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Nadja Smailagic; Marco Vacante; Chris Hyde; Steven Martin; Obioha Ukoumunne; Christos Sachpekidis
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

Review 4.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-03-22

Review 5.  Dementia and behavioral neurology: recent advances.

Authors:  Basar Bilgic; Hasmet A Hanagasi; Murat Emre
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

Review 6.  Recent advances in imaging Alzheimer's disease.

Authors:  Meredith N Braskie; Arthur W Toga; Paul M Thompson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

Authors:  Samantha Galluzzi; Cristina Geroldi; Giovanni Amicucci; Luisella Bocchio-Chiavetto; Matteo Bonetti; Cristian Bonvicini; Maria Cotelli; Roberta Ghidoni; Barbara Paghera; Orazio Zanetti; Giovanni B Frisoni
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

8.  Neuroimaging measures as endophenotypes in Alzheimer's disease.

Authors:  Meredith N Braskie; John M Ringman; Paul M Thompson
Journal:  Int J Alzheimers Dis       Date:  2011-03-31

Review 9.  A window into the heterogeneity of human cerebrospinal fluid Aβ peptides.

Authors:  Roberta Ghidoni; Anna Paterlini; Valentina Albertini; Elena Stoppani; Giuliano Binetti; Kjell Fuxe; Luisa Benussi; Luigi F Agnati
Journal:  J Biomed Biotechnol       Date:  2011-08-23

Review 10.  Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.